Compare Hormel Foods Corp (HRL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Illumina, Inc. — how do they compare? Hormel Foods Corp trades at $19.19 (market cap $10.69B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 3.7× Hormel Foods Corp's market cap, and Hormel Foods Corp pays a 6.02% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Illumina, Inc. for 83 Days on average.
| HRL | ILMN | |
|---|---|---|
Market Cap | $10.69B | $39.95B |
Volume | 10,041,387 | 3,169,503 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $293.69 |
52-Week Low | $19.19 | $91.00 |
Typical Hold Time | 99 Days | 83 Days |
Enterprise Value | $12.67B | $41.31B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.42, down 0.66% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, though it has beaten EPS estimates in recent quarters. Recent news highlights the $1.06B Brakebush acquisition to expand foodservice presence, while maintaining its 60-year dividend king status with a quarterly payout of $0.2925.
The outlook is cautious with analyst consensus at Buy 20%/Hold 57%/Sell 23% and a $24.25 price target suggesting 25% upside. Key risks include declining profit margins, high payout ratio concerns, and integration challenges from the Brakebush acquisition. The stock offers dividend stability but faces growth headwinds in a competitive food sector.
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
